$78.36
+2.5%Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Positive working capital, but relatively tight. The company should monitor cash flow carefully.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
SOLV โข NYSE
| Solventum Corporation Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
ASSETS | |||||
CURRENT ASSETS | |||||
878M | 762M | 194M | 61M | 91M | |
878M | 762M | 194M | 61M | 91M | |
1B | 1.2B | 1.3B | 1.2B | 1.2B | |
1B | 1B | 1.3B | 1.2B | 1.2B | |
0.0 | 185M | 0.0 | 0.0 | 0.0 | |
1.1B | 965M | 857M | 873M | 813M | |
881M | 293M | 155M | 126M | 108M | |
3.9B | 3.2B | 2.5B | 2.2B | 2.2B | |
NON-CURRENT ASSETS | |||||
1.3B | 1.6B | 1.5B | 1.3B | 1.3B | |
5.7B | 6.4B | 6.5B | 6.4B | 6.7B | |
2.6B | 2.5B | 2.9B | 3.3B | 3.7B | |
8.3B | 8.9B | 9.4B | 9.7B | 10.3B | |
813M | 665M | 530M | 358M | 253M | |
10.4B | 11.2B | 11.4B | 11.4B | 11.9B | |
14.3B | 14.5B | 13.9B | 13.6B | 14.1B | |
LIABILITIES | |||||
CURRENT LIABILITIES | |||||
687M | 1B | 583M | 348M | 320M | |
687M | 618M | 477M | 348M | 320M | |
0.0 | 394M | 106M | 0.0 | 0.0 | |
0.0 | 260M | 206M | 168M | 189M | |
0.0 | 200M | 0.0 | 0.0 | 0.0 | |
0.0 | 122M | 106M | 0.0 | 0.0 | |
621M | 572M | 574M | 559M | 574M | |
1.8B | 659M | 365M | 236M | 323M | |
3.1B | 2.7B | 1.7B | 1.3B | 1.4B | |
NON-CURRENT LIABILITIES | |||||
5B | 7.8B | 8.3B | 0.0 | 0.0 | |
164M | 225M | 231M | 215M | 218M | |
910M | 760M | -8B | 326M | 392M | |
6.1B | 8.8B | 549M | 541M | 610M | |
9.2B | 11.5B | 2.3B | 1.9B | 2B | |
SHAREHOLDERS' EQUITY | |||||
2M | 2M | 0.0 | 0.0 | 0.0 | |
0.0 | 3.8B | 0.0 | 0.0 | 0.0 | |
1.8B | 242M | 0.0 | 0.0 | 0.0 | |
-625M | -1.1B | -337M | -497M | -200M | |
3.9B | 0.0 | 12B | 12.2B | 12.3B | |
5B | 3B | 11.7B | 11.7B | 12.1B | |
5B | 3B | 11.7B | 11.7B | 12.1B | |
SUMMARY | |||||
14.3B | 14.5B | 13.9B | 13.6B | 14.1B | |
5B | 8B | 8.3B | 0.0 | 0.0 | |
4.2B | 7.2B | 8.1B | -61M | -91M | |
173,444,597 | 173,444,597 | 173,444,597 | 173,444,597 | 173,444,597 |
SOLV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 27, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 20, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 16, 2025 | December 16, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Continue your SOLV research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.